The blood–brain barrier (BBB) is a highly specialized neurovascular unit, initially described
as an intact barrier to prevent toxins, pathogens, and potentially harmful substances from …

The blood–brain barrier (BBB) is formed by brain microvascular endothelial cells that are
sealed by tight junctions, making it a significant obstacle for most brain therapeutics. The …

Ischemic stroke is a vascular central nervous system (CNS) disease that leads a disability
and death. Thrombolysis and neuroprotection are the primary treatment strategies of …

Clinically approved therapeutics associated with cancer are limited to mostly chemotherapy,
surgery and radiotherapy in spite of the advancements in the biomedical field. Due to the …

Yeast surface display (YSD) is a powerful tool in biotechnology that links genotype to
phenotype. In this review, the latest advancements in protein engineering and high …

The blood-brain barrier (BBB) hinders therapeutic delivery to the central nervous system
(CNS), thereby impeding the development of therapies for brain injury and disease …

The blood–brain barrier (BBB) represents a significant bottleneck for the delivery of
therapeutics to the central nervous system. In recent years, the promise of coopting BBB …

Drug delivery across the blood-brain barrier (BBB) remains a significant obstacle for the
development of neurological disease therapies. The low penetration of blood-borne …

A grand challenge in drug delivery is providing the right dose, at the right anatomic location,
for the right duration of time to maximize therapeutic efficacy while minimizing off-target …

Patients with glioblastoma (GBM) face a poor prognosis with a median survival of less than
two years. Escalating the dose of chemotherapy is often impossible due to patient …